Bovine Lymphocyte Antigen-A 11-Specific Peptide Motif as a Means to Identify Cytotoxic T-Lymphocyte Epitopes of Bovine Herpesvirus 1

1999 ◽  
Vol 12 (2) ◽  
pp. 149-161 ◽  
Author(s):  
NAGENDRA R. HEGDE ◽  
MURALIDHAR S. DESHPANDE ◽  
DALE L. GODSON ◽  
LORNE A. BABIUK ◽  
S. SRIKUMARAN
Vaccine ◽  
1999 ◽  
Vol 17 (7-8) ◽  
pp. 686-694 ◽  
Author(s):  
Douglas S. Zatechka ◽  
Nagendra R. Hegde ◽  
Kandasamy Hariharan ◽  
S. Srikumaran

Vaccine ◽  
2001 ◽  
Vol 19 (11-12) ◽  
pp. 1425-1434 ◽  
Author(s):  
Manjula Navaratnam ◽  
Muralidhar S Deshpande ◽  
Mangala J Hariharan ◽  
Douglas S Zatechka ◽  
S Srikumaran

1989 ◽  
Vol 63 (4) ◽  
pp. 1525-1530 ◽  
Author(s):  
J J Carter ◽  
A D Weinberg ◽  
A Pollard ◽  
R Reeves ◽  
J A Magnuson ◽  
...  

2013 ◽  
Vol 14 (1) ◽  
pp. 103-123 ◽  
Author(s):  
Randall L. Levings ◽  
James A. Roth

AbstractBovine herpesvirus 1 (BHV-1) infection is widespread and causes a variety of diseases. Although similar in many respects to the human immune response to human herpesvirus 1, the differences in the bovine virus proteins, immune system components and strategies, physiology, and lifestyle mean the bovine immune response to BHV-1 is unique. The innate immune system initially responds to infection, and primes a balanced adaptive immune response. Cell-mediated immunity, including cytotoxic T lymphocyte killing of infected cells, is critical to recovery from infection. Humoral immunity, including neutralizing antibody and antibody-dependent cell-mediated cytotoxicity, is important to prevention or control of (re-)infection. BHV-1 immune evasion strategies include suppression of major histocompatibility complex presentation of viral antigen, helper T-cell killing, and latency. Immune suppression caused by the virus potentiates secondary infections and contributes to the costly bovine respiratory disease complex. Vaccination against BHV-1 is widely practiced. The many vaccines reported include replicating and non-replicating, conventional and genetically engineered, as well as marker and non-marker preparations. Current development focuses on delivery of major BHV-1 glycoproteins to elicit a balanced, protective immune response, while excluding serologic markers and virulence or other undesirable factors. In North America, vaccines are used to prevent or reduce clinical signs, whereas in some European Union countries marker vaccines have been employed in the eradication of BHV-1 disease.


1998 ◽  
Vol 72 (9) ◽  
pp. 7040-7047 ◽  
Author(s):  
Chong Wang ◽  
Gary A. Splitter

ABSTRACT Bovine herpesvirus 1 (BHV-1) induces immune suppression, but the mechanisms for suppression are not well identified. We examined the induction and activity of BHV-1-specific cytolytic CD4+ T lymphocytes (CTL) by stimulating peripheral blood mononuclear cells (PBMC) of cattle immunized with attenuated live BHV-1. Cytolytic effector cells were primarily CD4+ T lymphocytes and lysed autologous, but not allogeneic, macrophages infected with BHV-1 or pulsed with BHV-1 polypeptides. Apoptosis of BHV-1-expressing target cells was observed in CD4+ CTL assays by terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling (TUNEL) analysis. To determine if apoptosis was mediated by a perforin- or Fas-mediated pathway, EGTA, a known selective inhibitor of the perforin pathway, was used. EGTA did not inhibit CD4+-T-cell-mediated cytotoxic activity, but it did limit the NK cell cytotoxicity of virus infected cells. These findings support the concept that CD4+ CTL lyse macrophages pulsed with BHV-1 polypeptides through a Fas-mediated lytic pathway by inducing apoptosis in the target cells. The prominent cytotoxicity mediated by CD4+ CTL suggests a mechanism of selective removal of viral antigen-associated antigen-presenting cells.


2005 ◽  
Vol 86 (4) ◽  
pp. 887-898 ◽  
Author(s):  
Y. Huang ◽  
L. A. Babiuk ◽  
S. van Drunen Littel-van den Hurk

Virus-specific cytotoxic T lymphocytes (CTLs) are considered to be important in protection against and recovery from viral infections. In this study, several approaches to induce cytotoxicity against bovine herpesvirus 1 (BHV-1) were evaluated. Vaccination of C57BL/6 mice with BHV-1 induced a strong humoral, but no CTL, response, which may be due to downregulation of major histocompatibility complex class I molecules. In contrast, vaccinia virus expressing glycoprotein B (gB) elicited a weaker antibody response, but strong cytotoxicity, in mice. As an approach to inducing both strong humoral and cellular immune responses, a plasmid vector was then used to express gB. Both antibody and CTL responses were induced by the plasmid encoding gB in C57BL/6 and C3H mice, regardless of the type of vector backbone. This demonstrated that DNA immunization induces a broad-based immune response to BHV-1 gB. Interestingly, removal of the membrane anchor, which resulted in secretion of gB from transfected cells, did not result in reduced cytotoxicity. Here, it is shown that, compared with the cell-associated counterpart, plasmid-encoded secreted protein may induce enhanced immune responses in cattle. Therefore, calves were immunized intradermally with pMASIAtgB, a plasmid encoding the secreted form of gB (tgB), using a needle-free injection system. This demonstrated that pMASIAtgB elicited both humoral responses and activated gamma interferon-secreting CD8+ CTLs, suggesting that a DNA vaccine expressing tgB induces a CTL response in the natural host of BHV-1.


Sign in / Sign up

Export Citation Format

Share Document